Join to View Full Profile
35 Park StreetSmilow Cancer Hospital at Yale-New HavenNew Haven, CT 06511
Dr. Krop is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Ian Krop, MD, PhD is the Chief Clinical Research Officer and Associate Cancer Center Director for Clinical Research at the Yale Cancer Center. He also serves as the Chief Scientific Officer for the Translational Breast Cancer Research Consortium (TBCRC).
Dr. Krop received his undergraduate, medical and PhD degrees from Johns Hopkins University. He subsequently completed his residency in Internal Medicine at Johns Hopkins Hospital, and fellowship in hematology and medical oncology at Dana-Farber.
Dr. Krop is a translational investigator focused on the development of novel molecularly targeted therapies and immunotherapies for breast cancer, and elucidating the mechanisms of resistance to these treatments. The majority of his effort is concentrated in the area of HER2+ breast cancer. He was a leader in the development of the antibody-drug conjugates trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan
Education & Training
Johns Hopkins University School of MedicinePhD, 1996
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1999 - 2002
Johns Hopkins University School of MedicineResidency, 1996 - 1999- Johns Hopkins University School of MedicineClass of 1996
Certifications & Licensure
FL State Medical License 2023 - Present
CT State Medical License 2022 - 2025
MA State Medical License 2002 - 2023
American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Multiplex Spatial Proteomic Analysis of HER2-Positive Breast Tumors Reveals Unique Molecular and Immunologic Features Associated With Treatment Response.Maeve A Hennessy, Ashley Cimino-Mathews, Jodi M Carter, Jennifer M Kachergus, Yaohua Ma
JCO Precision Oncology. 2025-04-01 - A compositeF-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026).Maeve A Hennessy, Ashley Cimino-Mathews, Jodi M Carter, Jennifer M Kachergus, Yaohua Ma
Breast. 2025-03-01 - 3 citationsPhase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advance...Komal L Jhaveri, Melissa K Accordino, Philippe L Bedard, Andrés Cervantes, Valentina Gambardella
Journal of Clinical Oncology. 2024-11-20
Press Mentions
Dr. Ian Krop and Alyssa Gateman on Yale Cancer Answers: Increasing Access to Clinical TrialsJanuary 13th, 2025- How Low Can You Go: Fam-Trastuzumab Deruxtecan-Nxki for HER2 Ultralow Metastatic Breast CancerJanuary 10th, 2025
- A Setback for TNBC Monitoring with Circulating Tumor DNA in ZEST TrialDecember 15th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
